Stock HZNP HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases Horizon Therapeutics Public Limited Company

Equities

HZNP

IE00BQPVQZ61

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
AMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS PLC
AQ
Rule 17(d) Announcement, Horizon Therapeutics plc
AQ
Rule 17(e) Announcement - Horizon Therapeutics plc
BU
Rule 17(d) Announcement – Horizon Therapeutics plc
BU
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
BU
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
BU
Horizon Therapeutics plc Announces New UPLIZNA Data in Neuromyelitis Optica Spectrum Disorder to be presented at ECTRIMS 2023
AQ
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
BU
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
BU
Horizon Therapeutics - New Analysis Highlights Importance of Adhering to Uninterrupted Full Course of Treatment with TEPEZZA to Support Thyroid Eye Disease Patient Outcomes
AQ
Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2023
BU
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
BU
New Analysis Highlights Importance of Adhering to Uninterrupted Full Course of Treatment with TEPEZZA® (teprotumumab-trbw) to Support Thyroid Eye Disease (TED) Patient Outcomes
BU
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
BU
Horizon Therapeutics plc Named to U.S. News & World Report's 2024 List of Best Companies to Work For in the Health Care Industry
AQ
Horizon Therapeutics plc Named to U.S. News & World Report’s 2024 List of Best Companies to Work For in the Health Care Industry
BU
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
BU
Horizon Therapeutics plc Ranks Number One on the Fortune Best Workplaces in Biopharma 2023 List
BU
Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia Areata
BU
FTC, States Agree On Path Forward For Amgen's Horizon Therapeutics Deal
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HZNP Stock
  4. News Horizon Therapeutics Public Limited Company
  5. Press Releases